

#### MEDISCA<sup>®</sup> NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 <u>technicalservices@medisca.net</u>

4/23/2013; Page 1

Suggested	Bupropion Hydrochloride 150 mg/5 mL Oral Liquid (Suspension, 150 mL)	FIN	F 001 555v2	ĺ
Formula	Dupropron frydroenionae 150 mg/5 mL Orar Erquia (Suspension, 150 mL)	1 11 4	1 001 333 12	1
ronnula				1

## SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Bupropion Hydrochloride, USP	4.500	g				
Propylene Glycol, USP	2.3	mL				
Medisca Oral Suspend (Suspending Vehicle)	72.7	mL				
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 150.0	mL				

# SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

*Hygroscopic* (protect from moisture whenever possible):

Light Sensitive (protect from light whenever possible):

Propylene	Glycol
-----------	--------

Bupropion Hydrochloride, Propylene Glycol

Suggested Preparatory Guidelines

Non-Sterile Preparat	ion Sterile Preparation
<u>Processing Error /</u> <u>Testing Considerations</u> :	To account for processing error considerations during preparation, it is suggested to measure an additional <b>3 to 5%</b> of the required quantities of ingredients.
Special Instruction:	Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



#### MEDISCA<sup>®</sup> NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/23/2013; Page 2

Suggested Formula	Bupropion Hydrochloride 150 mg/5 mL Oral Liquid (Suspension, 150 mL)	FIN	F 001 555v2	
----------------------	--	-----	-------------	--

#### SUGGESTED PREPARATION (for 150 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor <sup>(*)</sup> :	Processing Error	Qty. to measure
Bupropion Hydrochloride, USP §	4.500	g			
Propylene Glycol, USP §	2.3	mL			
Medisca Oral Suspend (Suspending Vehicle)	72.7	mL			
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 150.0	mL			

§ Weigh / measure just prior to use.

\* Takes into account increased batch size conversions and density conversions, if required.

# Preparatory Instruction

#### 1. **Powder-liquid preparation:**

A. Triturate the Bupropion Hydrochloride to form a fine, homogeneous powder.

B. Levigate the fine, homogeneous powder (Step 1A) with the Propylene Glycol.

End result: Homogeneous liquid-like dispersion.

# 2. Medium integration:

A. Incrementally add the homogeneous liquid-like dispersion (Step 1B) to the Oral Suspend (Suspending Vehicle).

Specifications: Continuously mix.

End result: Homogeneous liquid-like dispersion.

## 3. Filling to volume:

A. Add Oral Syrup (Flavored Vehicle) to the mixture (Step 2A) to fill to the required batch size (150.0 mL *plus* processing error adjustments).

Specifications: Continuously mix.

End result: Homogeneous liquid-like dispersion.



4.

#### MEDISCA<sup>®</sup> NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 <u>technicalservices@medisca.net</u>

4/23/2013; Page 3

Suggested Formula Bupropion Hydrochloride 150 mg/5 mL Oral Liquid (Suspension, 150 mL)	FIN	F 001 555v2
---	-----	-------------

## Product transfer:

A. Transfer the final product into the specified dispensing container (see "Packaging requirements").

<u>Note</u>: Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.

## SUGGESTED PRESENTATION

Estimated Beyond-Use Date		14 days, refrigerated, as per USP.	ted, as per Packaging Requirements				
	1	Use as directed. Do not exceed dose.	d prescribed	6	Cap tightly after use.		
	2	Keep out of reach of children.		7	Shake well before use.		
Auxiliary Labels	3	Consult your health care practite other prescription or over medications are currently being prescribed for future use.	-the-counter	8	Keep refrigerated. Do not freeze.		
	4	Do not take with alcohol, tranquilizers or other CNS depre		9	Protect from light.		
	5	May impair mental and/or phys Use care when operating machinery.					
Pharmacist Instructions	Ad	ld any auxiliary labels specific to t	he active to th	ne disj	pensing container as deemed necessary.		
Patient Instructions	Co	ntact your pharmacist in the event	of adverse re	actior	15.		



#### MEDISCA<sup>®</sup> NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/23/2013; Page 4

		Bupropion Hydrochloride 150 mg/5 mL Oral Liquid (Suspension, 150 mL)	FIN	F 001 555v2				
RE	REFERENCES							
	1. Solutions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding</i> . American Pharmaceutical Association; 1998: 157.							
	2.	Zyban. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2005. 2412.						
		Propylene Glycol. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4<sup>th</sup> Edition</i> . American Pharmaceutical Association; 2003: 521.						
		Bupropion Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 34<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2005: 287.						
		Bupropion Hydrochloride (Monograph). In: O'Neil MJ. <i>The Merck Index 13<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 252.						
		USP <795>. US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXV / National Formulary 20.</i> Rockville, MD: US Pharmacopeial Convention, Inc; 2001: 2053.						

7. Bupropion Hydrochloride. Thomson Micromedex. USP DI – Drug Information for the Health Care Professional, 26<sup>th</sup> Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 692.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.